Otsuka Naoaki

写真a

Title

Assistant Professor

Researcher Number(JSPS Kakenhi)

31002678

Date of Birth

1993

Mail Address

E-mail address

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Assistant Professor  

Research Interests 【 display / non-display 】

  • 睡眠障害

  • 概日リズム睡眠・覚醒障害

  • 双極症

Research Areas 【 display / non-display 】

  • Life Science / Psychiatry

Published Papers 【 display / non-display 】

  • Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials

    Maruki, T; Takeshima, M; Yoshizawa, K; Maeda, Y; Otsuka, N; Aoki, Y; Utsumi, T; Matsui, K; Tajika, A; Takaesu, Y

    PSYCHIATRY AND CLINICAL NEUROSCIENCES ( Psychiatry and Clinical Neurosciences )  79 ( 6 ) 306 - 318   2025.06 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    Combination therapy with antidepressants and sleep medications is a promising candidate treatment for major depressive disorder (MDD) with insomnia. This systematic review and meta-analysis examined the efficacy and safety of combination therapy with antidepressants and sleep medication for treating MDD with insomnia compared to antidepressant monotherapy by sleep medication class (benzodiazepine, Z-drug, melatonin receptor agonist, and orexin receptor antagonist). This study was preregistered with PROSPERO (CRD42025636571). PubMed, CENTRAL, and Embase were searched for double-blind randomized controlled trials published until June 2024, resulting in eight eligible studies (1945 participants; eszopiclone = 4, zolpidem = 2, triazolam = 1, ramelteon = 1). Meta-analyses were performed based on six trials of Z-drugs. Compared with antidepressant monotherapy, combination therapy with antidepressants and Z-drugs resulted in higher remission rates from depressive symptoms (risk ratio: 1.25, 95% confidence interval [CI]: 1.08-1.45, P = 0.003), greater improvement in depressive symptoms (standardized mean difference [SMD]: 0.17, 95% CI: 0.01-0.33, P = 0.04) and insomnia symptoms (SMD: 0.43, 95% CI: 0.28-0.59, P < 0.001) in the short-term (within 12 weeks), with no difference in safety outcomes except for dizziness. Combination therapy with antidepressants and Z-drugs may be more useful for MDD with insomnia symptoms than antidepressant monotherapy in the short term. However, this study did not evaluate the benefits and harms of long-term adjunctive Z-drug therapy. Further long-term studies are needed to draw definitive conclusions regarding the efficacy and safety of combination therapy with antidepressants and Z-drugs. Moreover, further research is warranted to assess whether the findings of this study are applicable to other sleep medication classes.

  • Depressive mixed state and anxious distress as risk factors for suicidal behavior during major depressive episodes

    Ota, K; Shinzato, H; Otsuka, N; Zamami, Y; Kurihara, K; Futenma, K; Kondo, T; Takaesu, Y

    SCIENTIFIC REPORTS ( Scientific Reports )  15 ( 1 ) 11918 - 11918   2025.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    Accurately assessing and predicting suicidal behavior in patients with depression are challenging for researchers and clinicians. We examined various risk factors for suicidal behavior during major depressive episodes (MDE), especially focusing on depressive mixed state (DMX) and anxious distress (AD). We recruited 187 patients with MDE and divided them into two groups-with and without suicidal behavior-defined as the cut-off score of 1 or more on the suicidal behavior sub-item in the quick inventory of depressive symptomatology-self report. The presence of DMX was defined as a total score of 13 or more on the self-administered 8-item questionnaire for DMX. We used multivariate logistic regression analysis with the presence or absence of suicidal behavior as a dependent variable for investigating factors associated with suicidal behavior. The with suicidal behavior group was younger and indicated a greater proportion of past suicide attempts, AD, and DMX than the without suicidal behavior group. Logistic regression analysis revealed that AD (P = 0.020) and DMX (P = 0.018) were significantly associated with suicidal behavior. AD and DMX may promote suicidal behavior during MDE. These two psychopathological features should be carefully monitored and intensively treated for the prevention of suicide-related events.

  • Elevated Brain-Derived Neurotrophic Factor Levels During Depressive Mixed States

    Otsuka, N; Takaesu, Y; Zamami, Y; Ota, K; Kurihara, K; Shinzato, H; Kondo, T

    PSYCHIATRY INVESTIGATION ( Psychiatry Investigation )  20 ( 11 ) 1027 - +   2023.11 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    OBJECTIVE: Neurotrophin-like brain-derived neurotrophic factor (BDNF) and pro-inflammatory cytokines may modulate the pathophysiology of mood disorders. Although several studies show alterations in these biomarkers during the depressive, manic, and euthymic states of mood disorders, evidence is lacking for those in a mixed state. Therefore, this study aimed to investigate the relationship between the depressive mixed state (DMX) and peripheral neurobiological factors. METHODS: We enrolled 136 patients with major depressive episodes. Depressive symptoms were assessed using the Quick Inventory of Depressive Symptomatology Self-Report Japanese version (QIDS-SR-J). The severity of DMX was assessed using the self-administered 12-item questionnaire (DMX-12). Categorical screening as DMX-positive (n=54) was determined by a cutoff score of 13 or more in the specific eight symptoms from the DMX-12; the remaining were DMX-negative (n=82). Serum BDNF, tumor necrosis factor-α, highsensitivity C-reactive protein, and interleukin-6 levels were measured. RESULTS: When comparing biomarkers between the DMX-positive and DMX-negative groups, higher serum BDNF concentration in the DMX-positive group than in the DMX-negative group was the only significant finding (p=0.009). A positive correlation existed between the total score of the eight specific symptoms of DMX-12 and the BDNF concentration (r=0.190, p=0.027). After adjustment for confounders, logistic regression analysis revealed that BDNF (odds ratio [OR]=1.07, 95% confidence interval [CI]=1.00-1.14, p=0.045), bipolar diagnosis (OR=3.43, 95% CI=1.36-8.66, p=0.009), and total QIDS-SR-J score (OR=1.29, 95% CI=1.15-1.43, p<0.001) were significantly associated with DMX positivity. CONCLUSION: BDNF was positively associated with DMX severity, suggesting that higher BDNF concentrations may be involved in the pathophysiology of DMX.

Other Papers 【 display / non-display 】

  • Differentiating "sleepiness": daytime sleepiness, difficulty in getting up: Mood disorders and circadian rhythm dysfunctions

    大塚直亮, 高江洲義和

    臨床精神医学   53 ( 1 )   2024

     

    J-GLOBAL

Grant-in-Aid for Scientific Research 【 display / non-display 】

  • Grant-in-Aid for Young Scientists

    Project Year: 2025.04  -  2028.03 

    Direct: 3,700,000 (YEN)  Overheads: 4,810,000 (YEN)  Total: 1,110,000 (YEN)

  • Grant-in-Aid for Young Scientists

    Project Year: 2025.04  -  2028.03 

    Direct: 3,700,000 (YEN)  Overheads: 4,810,000 (YEN)  Total: 1,110,000 (YEN)

  • Elucidation of the Pathophysiology of Bipolar Disorder Comorbid with Circadian Rhythm Disorders Using Neurons Derived from Induced Pluripotent Stem Cells

    Grant-in-Aid for Research Activity start-up

    Project Year: 2024.07  -  2026.03 

    Direct: 2,200,000 (YEN)  Overheads: 2,860,000 (YEN)  Total: 660,000 (YEN)

  • Elucidation of the Pathophysiology of Bipolar Disorder Comorbid with Circadian Rhythm Disorders Using Neurons Derived from Induced Pluripotent Stem Cells

    Grant-in-Aid for Research Activity start-up

    Project Year: 2024.07  -  2026.03 

    Direct: 2,200,000 (YEN)  Overheads: 2,860,000 (YEN)  Total: 660,000 (YEN)